VIR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VIR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vir Biotechnology's Enterprise Value is $406.74 Mil. Vir Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-621.02 Mil. Therefore, Vir Biotechnology's EV-to-EBIT ratio for today is -0.65.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Vir Biotechnology's Enterprise Value is $406.74 Mil. Vir Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-602.69 Mil. Therefore, Vir Biotechnology's EV-to-EBITDA ratio for today is -0.67.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Vir Biotechnology's Enterprise Value is $406.74 Mil. Vir Biotechnology's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $43.99 Mil. Therefore, Vir Biotechnology's EV-to-Revenue ratio for today is 9.25.
The historical data trend for Vir Biotechnology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Enterprise Value | Get a 7-Day Free Trial | 971.03 | 2,745.55 | 4,921.05 | 1,098.16 | -41.97 |
Vir Biotechnology Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Enterprise Value | Get a 7-Day Free Trial | 995.27 | 1,576.58 | -308.63 | -41.97 | 347.42 |
For the Biotechnology subindustry, Vir Biotechnology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Vir Biotechnology's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1355.89686 | + | 0 | + | 111.673 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 12.867 | + | 0 | - | 1522.409 |
= | -41.97 |
Vir Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1376.09972 | + | 0 | + | 109.171 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 11.913 | + | 0 | - | 1149.763 |
= | 347.42 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (NAS:VIR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Vir Biotechnology's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 406.740 | / | -621.015 | |
= | -0.65 |
Vir Biotechnology's current Enterprise Value is $406.74 Mil.
Vir Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-621.02 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Vir Biotechnology's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 406.740 | / | -602.685 | |
= | -0.67 |
Vir Biotechnology's current Enterprise Value is $406.74 Mil.
Vir Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-602.69 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Vir Biotechnology's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 406.740 | / | 43.986 | |
= | 9.25 |
Vir Biotechnology's current Enterprise Value is $406.74 Mil.
Vir Biotechnology's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Vir Biotechnology's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008 |
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Phillip Pang | officer: Chief Medical Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Steven J. Rice | officer: Chief Administrative Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Saira Ramasastry | director | 501 CANAL BLVD., RICHMOND CA 94804 |
Backer Marianne De | officer: Chief Executive Officer | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Ann M. Hanly | officer: Chief Technology Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Sung Lee | officer: Chief Financial Officer | 7000 MARINA BLVD, BRISBANE CA 94005 |
Johanna Friedl-naderer | officer: Chief Business Officer, Global | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
George A Scangos | director, officer: President and CEO | C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
Howard Horn | officer: CFO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Herbert Virgin | officer: EVP, Research & CSO | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Janet Napolitano | director | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Robert J More | director | 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001 |
From GuruFocus
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 07-26-2023
By Marketwired • 09-20-2023
By sperokesalga sperokesalga • 04-11-2023
By sperokesalga sperokesalga • 02-22-2023
By sperokesalga sperokesalga • 05-15-2023
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 06-07-2023
By sperokesalga sperokesalga • 05-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.